Dimerix Limited announced it has been awarded a further AUD 100,000 from the Australian Government's Medical Research Future Fund through the Biomedical Translation Bridge program to support commercialisation of Dimerix lead candidate, DMX-200, in patients with COVID-19. The original Agreement between the parties, entered into in September 2020,1 has also been extended by a further 6 months (to 15 August 2022) to support the commercialisation efforts, which include business development and partnering activities. Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality. Dimerix' existing clinical drug candidate, DMX-200, was selected for inclusion in the global REMAP-CAP study for patients with respiratory complications associated with COVID-19.3 DMX-200 therapy is aimed at reducing damage from inflammatory immune cells by blocking their signalling and limiting subsequent movement. Patients hospitalised with COVID-19 commonly have acute lung dysfunction due to the immune response to the virus. The company's approach is based on a clear scientific rationale, is unique and potentially complementary to others being investigated globally, and importantly if effective in this study, would likely be effective against any strain as well as potentially other pneumonias with a common mechanism of action.4 Dimerix lead drug candidate, DMX-200, is being studied as part of two different investigator-led feasibility/Phase 3 studies in COVID-19 patients with respiratory complications, REMAP-CAP3 and CLARITY 2.0.5 Dimerix proactively supports both studies driven by the REMAP-CAP and CLARITY 2.0 teams in providing them information for the regulatory submissions and in supplying DMX-200 to the study sites. Dimerix looks forward to reporting on progress and as key milestones are met. In addition to the two COVID-19 clinical studies, Dimerix continues to progress the Phase 3 pivotal program in FSGS, a rare kidney disorder without an approved pharmacologic treatment that often leads to end-stage kidney failure, as well as assess the next study design in diabetic kidney disease patients and finally advance the COPD program towards the clinical stage of development.